Completed PHASE2 INTERVENTIONAL NCT00390624

Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol

Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.

Sponsor: Rocky Mountain Cancer Centers

Conditions Acute Renal Failure Mortality Renal Dysfunction

Interventions MANNITOL URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)

Updated 6 times since 2017 Last updated: May 30, 2008 Started: Jul 31, 2003 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Renal Failure and Mortality and is currently completed. Rocky Mountain Cancer Centers leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rocky Mountain Cancer Centers
University of Colorado, Denver

Data source: Rocky Mountain Cancer Centers

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Denver, United States